ARCHIVES

House Encourages NCI To continue Leadership Role As Coordinator Of Cancer Program

This article is from The Cancer Letter archive.

Vol. 25 No. 38 | October 8, 1999

Download PDF Visit The Full Archive

Related Articles

Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction.

April 21, 2006

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001

FDA Adopts Final Diagnostics X-Ray Rule Amendment

September 9, 1977

“Critical Issues” Include How U.S. NCI Spends Its Money. “Catastrophic” Cutback In Canada

May 14, 1976

How the Institute Fared In House Markup: Chart

July 18, 1997

In Brief: Progress Reported In NCI-FDA Fight Over New Drug Tests, Epidemiology Branch Reorganized

December 12, 1975